Intellectual Property India Publishes Patent Application for 'RNAI Agents For Inhibiting Expression Of DM1 Protein Kinase (DMPK) Compositions Thereof, And Methods Of Use' Filed by Arrowhead Pharmaceuticals, Inc.

MUMBAI, India, June 13 -- Intellectual Property India has published a patent application (202517045970 A) filed by Arrowhead Pharmaceuticals, Inc., Pasadena, U.S.A., on May 13, for 'rnai agents for inhibiting expression of dm1 protein kinase (dmpk) compositions thereof, and methods of use.'

Inventor(s) include Van Dyke, Jonathan; Ai, Teng; Li, Xiaokai; Ding, Zhi-Ming; Pei, Tao; and Schienebeck, Casi.

The application for the patent was published on June 13, under issue no. 24/2025.

According to the abstract released by the Intellectual Property India: "Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of DM1 protein kinase (DMPK) gene. The DMPK RNAi agents and RNAi agent conjugates disclosed here...